Choose a model
Each card values Vitrolife AB a different way, shown at our starting inputs. Pick one to see and change how it works.
Set your assumptions
Vitrolife AB on free cash flow: free cash flow per share, the cash left after investment, grows and is priced at a normal multiple.
Years to project
Growth of free cash flow per share
Free cash flow per share; starts at its own recent growth
Exit P/FCF
Starts at its own median P/FCF over five years
Your desired return
Margin of safety
More
Your buy price
The expected return is measured from it; starts at today's price
How it's worked out
Today's free cash flow per share
Last twelve months
kr 4.03
Free cash flow in 2031
Grows 0.6% a year for 5 years
kr 4.15
Price in 2031
kr 4.15 × 35.0 P/FCF
kr 145.40
Worth today
÷ 1.10^5: your 10% a year, taken back out
kr 90.28
Plus dividends
kr 5.60 paid over 5 years, discounted the same way
+ kr 4.24
Fair value
The most you can pay and still earn 10% a year
kr 94.52
Buy below
Fair value minus your 25% margin of safety
kr 70.89
Paying kr 118.20 instead gives 5.0% a year. Every rule is on the methodology page.
Outcome
What your assumptions give, and the path from today's price.
Fair value
kr 94.52
Expected return
5.0% a year
Future price, 2031
kr 145.40
Buy below
kr 70.89
Price 25% above fair valuePrice kr 118.20, at your 10% return
Projection
Solid blue: the price at each year end. Dashed blue: from today's price to the 2031 price. Green: from the fair value, rising at your 10% a year to the same end point; buy at or below it and you earn at least that. Every rule is on the methodology page. A model, not a forecast or advice.
Build your own intrinsic value for Vitrolife AB. Start from three cases based on the company's own filings, then change any number to match your view.
Conservative
kr 73.93
37% below the priceof kr 118.20
Buy below kr 55.45 for a 25% safety margin
Your assumptions
Base
kr 121.38
3% above the priceof kr 118.20
Buy below kr 91.04 for a 25% safety margin
Your assumptions
Optimistic
kr 185.28
57% above the priceof kr 118.20
Buy below kr 138.96 for a 25% safety margin
Your assumptions
Where today's price sits
Today's price falls inside the modelled range.
Verdict
Today's price sits inside the range, 3% below the base case. Whether that is a discount depends entirely on the base case growth holding.
Base free cash flow
kr 546M
Trailing twelve months
Historical FCF CAGR
+11.2%
Across 6 reported periods
Market implies
10.8%
Growth needed at 8% WACC
Terminal value share
65%
Of the base case valuation
Growth needed to justify today's price
At a 8.0% discount rate, today's price already assumes 10.8% annual free cash flow growth for ten years. Your base case assumes 11.2%, which is effectively the same bet.
Curve holds terminal growth at 2.5%, years 6 to 10 at half the first-stage rate, and applies no safety margin.
Free cash flow history
The most recent period is the base every projection starts from. Compounded, that history is +11.2% a year.
Vitrolife AB (VITR.XSTO) intrinsic value and fair value
The calculator grows one of Vitrolife AB's per-share figures (earnings, free cash flow, revenue, book value or dividends) for a few years, puts an exit multiple on it, and discounts the result back at the yearly return you want. The answers below use its starting inputs for VITR.XSTO; this is analysis, not investment advice.
Frequently asked
What is Vitrolife AB's (VITR.XSTO) intrinsic value?+
With Intrinsiqq's starting inputs, Vitrolife AB's fair value is about kr 94.52 a share, based on its free cash flow per share. That assumes free cash flow per share of kr 4.03 grows about 0.6% a year for 5 years, the stock then trades at 35.0 times free cash flow, and you want a 10.0% yearly return. On its other figures: revenue kr 228.49. Every input can be changed on the page; the result is a model, not a forecast.
Is Vitrolife AB overvalued?+
At kr 118.20, the price is 25% above that fair value of kr 94.52, and buying at today's price would return about 5.0% a year if those inputs hold. Whether that is cheap or dear depends on whether you believe the growth and the exit multiple, which is what the calculator lets you test. This is analysis from company filings, not investment advice.
What growth does the Vitrolife AB valuation assume?+
Free cash flow per share grows about 0.6% a year to start, its own recent growth per share (three years for a company not yet profitable, five otherwise). The exit multiple starts at its own median over five years.
What is a good margin of safety for Vitrolife AB?+
A margin of safety is the cushion you want below the fair value before buying, in case the inputs are wrong. The calculator uses 25%, which puts the buy-below price at kr 70.89. Less predictable businesses deserve a wider cushion, or a higher desired return.
Peers
Medical Devices · Pick stocks to compare with VITR.XSTO
Held by ETFs
VITR.XSTO is in 4 US ETFs. The largest of them, with VITR.XSTO's weight in each:
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing VITR.XSTO
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.